Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Obagi Medical Products, a provider of topical aesthetic and therapeutic skin health systems, has expanded its relationship with Rohto Pharmaceutical Co, a manufacturer of over-the-counter products, and Obagi's marketing and distribution partner, in Japan.
Subscribe to our email newsletter
Together, the companies will launch a series of products with ELASTIderm’s technology into consumer sales and distribution channels in Japan, including premium retail distribution channels, as well as jointly develop other scientifically based skin care products for the Japanese market.
Under the terms of the licensing agreement, Rohto will manufacture and sell ELASTIderm’s technology-based products into as many as 5,000 drug and variety stores under the Obagi brand. Under an existing agreement, Rohto manufactures and distributes Obagi-branded vitamin C, platinum and triple peel products.
In a related development, Obagi and Rohto have formed a collaborative effort to develop future science-based skin care solutions that Rohto will have the exclusive right to distribute in premium retail outlets in Japan.
Steve Carlson, president and CEO of Obagi Medical, said: We are very excited about expanding our relationship with Rohto. Rohto’s position as a market leader in the over-the-counter variety and drug store markets, and their expansion into the department store and other premium distribution channels in Japan will help us grow market share and revenue. The initial introduction of ELASTIderm, which is clinically proven to show an improvement in elastin production, will help us begin to achieve these goals.